Remove topic biotech
article thumbnail

Krystal Biotech receives FDA approval for DEB topical gene therapy

Pharmaceutical Technology

Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy

Fierce Pharma

Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million.

309
309
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Krystal's topical gene therapy gains steam, prompting analyst group to boost sales projection

Fierce Pharma

At the start of its first-ever conference call to present its quarterly numbers, Krystal Biotech CEO Krish Krishnan was quick to point out that the company’s positive earnings for the third quarter | Krystal Biotech's launch of Vyjuvek, the world's first topical gene therapy, has been so promising that analysts with Evercore ISI increased (..)

Sales 296
article thumbnail

Krystal Biotech’s B-VEC Topical Gene Therapy Shows Promise in Treating Rare Skin Disease

PM360

Krystal Biotech, Inc. , Participants were treated weekly with the topical B-VEC therapy. “In Patients had a primary wound pair identified, and one wound was randomized to receive a weekly topical application of B-VEC and the other a placebo. The topical gel was applied weekly until the wound was completely closed.

Safety 104
article thumbnail

First redosable gene therapy approved

European Pharmaceutical Review

The gene therapy is a topical gel that restores functional copies of the COL7A1 gene to provide wound healing and sustained functional COL7 protein expression with redosing. DEB affects the skin and mucosal tissues caused by one or more mutations in the COL7A1 gene, according to Krystal Biotech.

article thumbnail

Data Analytics Applications in Animal Health Bio-Technology

Celeritas

Getting quick, detailed, and accurate reports on animal health related topics a game-changer. Red Biotech: the research and creation of medicinal and veterinary products Red Biotech is by far the most common and has the greatest number of applications so don’t panic when you see the size of this section.

Food 98
article thumbnail

NKGen Biotech signs agreement to merge with Graf Acquisition

Pharmaceutical Technology

NKGen Biotech, a clinical-stage natural killer (NK) cell therapy firm, has signed a definitive agreement to combine its business operations with Graf Acquisition. NKGen Biotech will become a publicly traded company, while Graf will be rebranded as NKGen Biotech.